Revolution goes adjuvant
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
Adlai puts its faith in pan-RAS
The company’s AN9025 will shortly enter phase 1.
J&J tries to outdo Tecvayli
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
Chinese biotechs push on into the clinic
Car-T therapies and ADCs feature among recent first-in-human study entrants.
After SpringWorks, Immunome has a Ringside seat
Varegacestat’s pivotal study reads out imminently.
Summit joins the global colorectal fight
The pivotal Harmoni-GI3 study has started enrolling patients.
HengRui goes pivotal in KRAS G12D
The group will take HRS-4642 into a Chinese phase 3 in first-line pancreatic cancer.
The month ahead: December’s upcoming events
ASH and SABCS approach.
